Connor, Clark & Lunn Investment Management Ltd. 89bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$15.06 - $19.41 $1.56 Million - $2.01 Million	-103,617 Reduced 48.86%	108,441 $1.67 Million
Q2 2023 Aug 10, 2023	BUY	$14.15 - $22.03 $1.74 Million - $2.7 Million	122,719 Added 137.36%	212,058 $4.02 Million
Q1 2023 May 09, 2023	BUY	$10.48 - $16.94 $936,272 - $1.51 Million	89,339 New	89,339 $1.36 Million
Q3 2022 Nov 10, 2022	BUY	$3.02 - $7.0 $54,858 - $127,155	18,165 New	18,165 $105,000

Others Institutions Holding ETNB

# of Institutions

158

Shares Held

108M

Call Options Held

73.6K

Put Options Held

1.19M

Janus Henderson Group PLC London, X0

15.2M
Shares

$135 Million
0.06% of portfolio
Ra Capital Management, L.P. Boston, MA

14.2M
Shares

$126 Million
1.46% of portfolio
Suvretta Capital Management, LLC New York, NY

7.99M
Shares

$71.3 Million
2.33% of portfolio
Rtw Investments, LP New York, NY

7.38M
Shares

$65.8 Million
0.87% of portfolio
Black Rock Inc. New York, NY

7.02M
Shares

$62.6 Million
0.0% of portfolio

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account